You are here

  • Home
  • Online First
  • Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis

Article Text

Article menu

other Versions

Download PDFPDF
Basic and translational research
Extended report
Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis
  1. L van Bon1,2,
  2. C Popa1,
  3. R Huijbens1,
  4. M Vonk1,
  5. M York2,
  6. R Simms2,
  7. R Hesselstrand3,
  8. D M Wuttge3,
  9. R Lafyatis2,
  10. T R D J Radstake1,2
  1. 1Department of Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
  2. 2The Arthritis Center, Boston University School of Medicine, Boston, Massachusetts, USA
  3. 3Department of Rheumatology, Lund University Hospital, Lund, Sweden
  1. Correspondence to Dr Timothy R D J Radstake, Department of Rheumatology, Geert Grooteplein 8, 6500 HB Nijmegen, The Netherlands; t.radstake{at}reuma.umcn.nl

Abstract

Background Systemic sclerosis (SSc) is an autoimmune disease and accumulating evidence suggests a role for Toll-like receptor (TLR)-mediated activation of dendritic cells (DCs).

Objective To map TLR-mediated cytokine responses of DCs from patients with SSc.

Methods 45 patients with SSc were included. Patients were stratified as having diffuse cutaneous SSc (dSSc) or limited cutaneous SSc (lSSc) according to the extent of skin involvement, and further divided into those with late (>3 years) or early disease (<2 years). DCs were stimulated with ligands for TLR2, TLR3, TLR4, TLR7/8 or combinations. Plasma samples were collected from patients with SSc (n=167) and measured for interleukin 6 (IL-6), tumour necrosis factor α (TNFα), IL-12, IL-10 and interferon γ.

Results Stimulation of DC subsets from patients with early lSSc and dSSc with ligands for TLR2, TLR3 or TLR4 resulted in higher secretion of IL-6 and TNFα compared with those having late disease or healthy controls. Remarkably, the production of IL-12 was lower upon stimulation with TLR ligands in most patients with SSc, whereas the secretion of IL-10 was very high in patients with the dSSc phenotype, particularly in those having early dSSc. The combination of various TLR ligands led to reduced cytokine secretion in all patients with SSc. Circulating levels of these cytokines further underscored the presence of differences between various SSc phenotypes.

Discussion The altered TLR-mediated activation of DCs may be responsible for Th2 skewed T-cell activation in SSc that may be orchestrated by fibrogenic T-cell cytokines, such as IL-4 and IL-13. DC targeting could thus offer new avenues for therapeutic intervention.

https://doi.org/10.1136/ard.2009.128207

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • LvB and CP contributed equally to this work.

    • Funding CP was funded by an unrestricted grant from ‘Het Landelijk Katholiek Reuma Centrum (LKRC)’. The Post-doctoral programme (TRDJR) was funded by the Termeulen Stipendium from the KNAW, Netherlands. The work presented here was partly funded by the VIDI laureate (TRDJR) from the Dutch Organisation of Research (NWO). Support was also provided by grants to RL from the National Institutes of Health (NIAMS U01AR055063) and an unrestricted grant from the American Society for Scleroderma Research.

    • Competing interests None.

    • Ethics approval This study was conducted with the approval of the local ethical committees University Nijmegen and Boston.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Patient consent Obtained.